Hepatocellular carcinoma Trials in Chiang Mai, Thailand
Conditions / Hepatocellular carcinoma / Chiang Mai, Thailand
Hepatocellular carcinoma is a medical condition with active clinical research programs worldwide.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03778957 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | — |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03628651 | Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma | COMPLETED | — |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE3 |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03867084 | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | COMPLETED | — |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | COMPLETED | PHASE2 |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | RECRUITING | PHASE3 |